<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VANDAZOLE- metronidazoleÂ gelÂ </strong><br>Upsher-Smith Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VANDAZOLE<span class="Sup">Â®</span> safely and effectively.  See full prescribing information for VANDAZOLE<span class="Sup">Â®</span>.<br><br>VANDAZOLE<span class="Sup">Â®</span> (metronidazole vaginal gel, 0.75%) for intravaginal use.<br>Initial U.S. Approval: 1963</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><dl>
<dt>Â </dt>
<dd>VANDAZOLEÂ  is a nitroimidazole antimicrobial indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> in non-pregnant women. (<a href="#i4i_indications_id_fe3eb98e-a696-477d-81b4-a1040bf972ff">1</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>One applicator full of VANDAZOLEÂ  administered intravaginally once a day for 5 days. (<a href="#i4i_dosage_admin_id_a0de5e5c-3117-48e8-9959-ef4f9c74972d">2</a>)</li>
<li>Not for ophthalmic, dermal, or oral use. (<a href="#i4i_dosage_admin_id_a0de5e5c-3117-48e8-9959-ef4f9c74972d">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>Â </dt>
<dd>Vaginal gel 0.75% in a 70 g tube with 5 vaginal applicators (each applicator delivers approximately 5 g of gel containing 37.5 mg of metronidazole) (<a href="#i4i_dosage_form_strength_id_af2cc599-a00f-4da6-a984-599f4a2e8806">3</a>).</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<dl>
<dt>Â </dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole, other nitroimidazole derivatives or parabens (<a href="#i4i_contraindications_id_1c4541c7-5a31-459b-a5eb-8c43097bbc8d">4</a>)</dd>
</dl>
<ul>
<li>Disulfiram: <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported with disulfiram and oral metronidazole; do not administer concurrently with or within the last 2 weeks of disulfiram (<a href="#i4i_section_id_98cb0c9d-7ce1-4131-bc21-984c1abe325e">4.2</a>, <a href="#i4i_section_id_4fde7f85-40bd-4ae0-b227-688591b87d99">7.1</a>).</li>
<li>Alcohol: Disulfiram-like reactions to alcohol have been reported with oral metronidazole; do not consume alcohol during and for at least three days following treatment (<a href="#i4i_section_id_97bf5f4b-bf64-40f4-9322-659929a88714">4.3</a>, <a href="#i4i_section_id_1cc53620-cde0-4bdf-810e-9d189f1e5bf6">7.2</a>)<p class="Highlighta"> </p>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Central and Peripheral Nervous System Effects: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> have been reported in patients treated with oral or intravenous metronidazole; Discontinue promptly if abnormal neurologic signs develop. (<a href="#i4i_section_id_9d4a13b3-cda9-44ce-aa41-acb8c214e2b2">5.1</a>)</li>
<li>Carcinogenicity in Animals: Metronidazole has been shown to be carcinogenic in mice and rats; unnecessary use should be avoided (<a href="#i4i_section_id_6142fe0e-a633-415e-86d1-08f6c6fe7336">5.2</a>, <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_7ec24807-6ab6-465a-b59a-b2250f20fec6">13.1</a>)</li>
<li>Interference with laboratory tests: Metronidazole may interfere with certain serum chemistry laboratory values (<a href="#i4i_section_id_c6aba1ec-0da7-4aa6-a63f-9ecc8b7e84eb">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions occurring in â‰¥ 1% of patients are: <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, and <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>. (<a href="#i4i_section_id_c9fc8ffc-4f44-4378-97e9-2250b09ca7a8">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-888-838-2872, X6351 or drug.safety@tevausa.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  </span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Warfarin and other coumarin anticoagulants: Prolonged anticoagulant effects reported with oral metronidazole; monitor INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. (<a href="#i4i_section_id_031c4a2d-a899-45a6-9faf-1c036484b0cf">7.3</a>)</li>
<li>Lithium: Elevated lithium concentrations reported with oral metronidazole; monitor serum concentrations of lithium. (<a href="#i4i_section_id_c5c21511-18d9-4c63-a107-3f279d658b13">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Nursing Mothers: Caution should be exercised when administered to a nursing woman (<a href="#i4i_nursing_mothers_id_3ad0e05c-f56a-424d-b617-3d5754cd4ddb">8.3</a>).</li></ul></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reaction</span> with Disulfiram</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Interaction with Alcohol</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Central and Peripheral Nervous System Effects</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Carcinogenicity in Animals</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Interference with Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Other Metronidazole Formulations</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Disulfiram</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Alcoholic Beverages</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Coumarin and Other Oral Anticoagulants</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Lithium</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Cimetidine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Interaction with Alcohol</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Drug Interactions</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Vaginal Intercourse and Use with Vaginal Products</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Fungal <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal Infections</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Human Milk Feeding</a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Accidental Exposure to the Eye</a></h2>
<h2><a href="#section-15.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">Vaginal Irritation</span></a></h2>
<h2><a href="#section-15.8" class="toc">17.8 Administration of Drug</a></h2>
<h2><a href="#section-18.1" class="toc">Vandazole (Metronidazole Vaginal Gel, 0.75%) 70 grams Tube, Carton Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fe3eb98e-a696-477d-81b4-a1040bf972ff"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">VANDAZOLEÂ  is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> (formerly referred to as <span class="Italics">Haemophilus </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Gardnerella </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, nonspecific <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Corynebacterium </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, or anaerobic vaginosis) in non-pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a0de5e5c-3117-48e8-9959-ef4f9c74972d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one applicator full of VANDAZOLEÂ , (approximately 5 grams of gel containing approximately 37.5 mg of metronidazole) administered intravaginally once a day for 5 days. For once a day dosing, VANDAZOLEÂ  should be administered at bedtime [<span class="Italics">see Patient Counseling Information (<a href="#i4i_section_id_33ce28b3-6647-46b6-b509-0294820223e5">17.4</a>)</span>].</p>
<p>Not for ophthalmic, dermal, or oral use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_af2cc599-a00f-4da6-a984-599f4a2e8806"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">VANDAZOLE is a vaginal gel 0.75% in a 70 g tube with 5 vaginal applicators (each applicator delivers approximately 5 g of gel containing 37.5 mg of metronidazole). </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1c4541c7-5a31-459b-a5eb-8c43097bbc8d"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abf2b56c-71a0-4473-a60f-9b6283db8f99"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">The use of VANDAZOLE is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole, other nitroimidazole derivatives, or parabens. Reported reactions include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>; dryness of the mouth, vagina, or vulva; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; fleeting <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span> [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_12058a6d-7c80-44f3-95b0-f5034dbd72c5">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98cb0c9d-7ce1-4131-bc21-984c1abe325e"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reaction</span> with Disulfiram</h2>
<p class="First">Use of oral metronidazole is associated with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> in alcoholic patients who were using disulfiram concurrently. Do not administer VANDAZOLE to patients who have taken disulfiram within the last two weeks [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_12058a6d-7c80-44f3-95b0-f5034dbd72c5">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97bf5f4b-bf64-40f4-9322-659929a88714"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Interaction with Alcohol</h2>
<p class="First">Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_12058a6d-7c80-44f3-95b0-f5034dbd72c5">6.2</a>)</span>]. Discontinue alcohol consumption during and for at least three days after therapy with VANDAZOLE.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_2a95692f-61c3-4d31-9cca-089dab5837c9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d4a13b3-cda9-44ce-aa41-acb8c214e2b2"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Central and Peripheral Nervous System Effects</h2>
<p class="First">Use of oral or intravenous metronidazole is associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or parethesia of an extremity [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_12058a6d-7c80-44f3-95b0-f5034dbd72c5">6.2</a>)</span>]. VANDAZOLE should be administered with caution to patients with central nervous system diseases. Discontinue VANDAZOLE promptly if a patient develops abnormal neurologic signs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6142fe0e-a633-415e-86d1-08f6c6fe7336"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Carcinogenicity in Animals</h2>
<p class="First">Metronidazole has been shown to be carcinogenic in mice and rats [<span class="Italics">see Carcinogenesis, Mutagenesis, Impairment of Fertility (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_7ec24807-6ab6-465a-b59a-b2250f20fec6">13.1</a>)</span>]. Unnecessary use of metronidazole should be avoided. Use of VANDAZOLE should be reserved for the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> [<span class="Italics">see Indications and Usage (<a href="#i4i_indications_id_fe3eb98e-a696-477d-81b4-a1040bf972ff">1</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6aba1ec-0da7-4aa6-a63f-9ecc8b7e84eb"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Interference with Laboratory Tests</h2>
<p class="First">Metronidazole may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), alanine aminostransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide-adenine dinucleotides (NAD + NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7. Consider postponing chemistry laboratory tests to after treatment with VANDAZOLE.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_676b0605-ddce-411e-89a5-2f8498472738"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9fc8ffc-4f44-4378-97e9-2250b09ca7a8"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to VANDAZOLE compared to another formulation of vaginal metronidazole in 220 women in a single trial. The population was non-pregnant females (age range 18 to 72 years, the mean was 33 years +/- 11 years) with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. The racial demographic of those enrolled was 71 (32%) of White, 143 (65%) of Black, 3 (1%) of Hispanic, 2 (1%) of Asian, and 1 (0%) of other. Patients administered an applicator full of VANDAZOLE intravaginally once daily at bedtime for 5 days.</p>
<p>There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or serious adverse reactions related to drug therapy in the clinical trial. VANDAZOLE was discontinued in 5 patients (2.3%) due to adverse reactions. </p>
<p>The incidence of all adverse reactions in VANDAZOLE-treated patients was 42% (92/220). Adverse reactions occurring in â‰¥ 1% of patients were: <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>* (12%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (6%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (3%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (2%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (1%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1%), <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> (1%), and <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span> (1%).</p>
<p>* Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> may present more prominent symptoms during therapy with VANDAZOLE. Approximately 10% of patients treated with VANDAZOLE developed <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> during or immediately after therapy.</p>
<p>Additional uncommon events, reported by &lt; 1% of those women treated with VANDAZOLE included:</p>
<a name="id_70b5551c-4005-4ba7-b091-ade3a4b2d120"></a><table width="378">
<col width="35.7%">
<col width="64.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
<span class="Italics">General:</span><span class="Italics">Â </span>
</td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">mucous membrane disorder</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Italics">Gastrointestinal:</span></td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Italics">Nervous System:</span></td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Italics">Respiratory System:</span></td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Italics">Skin and Appendages:</span></td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<span class="Italics">Urogenital System:</span> Â  <span class="Italics">Â </span>
</td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, female lactation, labial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, leucorrhea, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, pyleonephritis, <span class="product-label-link" type="condition" conceptid="4338958" conceptname="Salpingitis">salpingitis</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="4051956" conceptname="Vulvovaginal disease">vulvovaginal disorder</span> </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12058a6d-7c80-44f3-95b0-f5034dbd72c5"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Other Metronidazole Formulations</h2>
<p class="First"><span class="Italics">Other Vaginal Formulations</span></p>
<p>Other reactions that have been reported in association with the use of other formulations of metronidazole vaginal gel include: unusual taste and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>.</p>
<p><span class="Italics">Topical (Dermal) Formulations</span></p>
<p>Other reactions that have been reported in association with the use of topical (dermal) formulations of metronidazole include <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>, and mild skin dryness and burning. None of these adverse reactions exceeded an incidence of 2% of patients.</p>
<p><span class="Italics">Oral and Parenteral Formulations</span></p>
<p>The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of metronidazole:</p>
<p><span class="Italics">Cardiovascular: </span>Flattening of the T-wave may be seen in electrocardiographic tracings.</p>
<p><span class="Italics">Nervous System:</span> The most serious adverse reactions reported in patients treated with metronidazole have been <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity. In addition, patients have reported <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. [<span class="Italics">see Warnings and Precautions (5.1)</span>]</p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, an unpleasant metallic taste, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, abdominal cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, â€œfurryâ€? tongue, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and modification of taste of alcoholic beverages.</p>
<p><span class="Italics">Genitourinary:</span> Overgrowth of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> in the vagina, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>.</p>
<p><span class="Italics">Hematopoietic:</span> Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>; erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>; dryness of the mouth, vagina, or vulva; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; fleeting <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span> [<span class="Italics">see Contraindications (<a href="#i4i_section_id_abf2b56c-71a0-4473-a60f-9b6283db8f99">4.1</a>)</span>].</p>
<p><span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, a sense of pelvic pressure, darkened urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_06cc6d33-099d-4139-8cba-44459bf22678"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The intravaginal administration of a single 5 gram dose of VANDAZOLE results in relatively lower mean systemic exposure to metronidazole that is approximately 2% to 5% of that achieved following a 500 mg oral dose of metronidazole [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_3fc2a706-fed6-41e8-8c43-11935da62b71">12.3</a>)</span>]. The following drug interactions were reported for oral metronidazole.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4fde7f85-40bd-4ae0-b227-688591b87d99"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Disulfiram</h2>
<p class="First">Use of oral metronidazole has been associated with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> in alcoholic patients who are using disulfiram concurrently. VANDAZOLE should not be used by patients who have taken disulfiram within the last two weeks [<span class="Italics">see Contraindications (<a href="#i4i_section_id_98cb0c9d-7ce1-4131-bc21-984c1abe325e">4.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1cc53620-cde0-4bdf-810e-9d189f1e5bf6"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Alcoholic Beverages</h2>
<p class="First">Use of oral metronidazole has been associated with a disulfiram-like reaction (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>) to alcohol. Alcoholic beverages and preparations containing ethanol or propylene glycol should not be consumed during and for at least three days after VANDAZOLE therapy [<span class="Italics">see Contraindications (<a href="#i4i_section_id_97bf5f4b-bf64-40f4-9322-659929a88714">4.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_031c4a2d-a899-45a6-9faf-1c036484b0cf"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Coumarin and Other Oral Anticoagulants</h2>
<p class="First">Use of oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This possible drug interaction should be considered when VANDAZOLE is prescribed for patients on this type of anticoagulant therapy. In patients on oral anticoagulants, consider monitoring <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, international normalized ratio (INR), and other coagulation parameters while on VANDAZOLE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5c21511-18d9-4c63-a107-3f279d658b13"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Lithium</h2>
<p class="First">Short-term use of oral metronidazole has been associated with elevation of serum lithium concentrations and, in a few cases signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>, in patients stabilized on relatively high doses of lithium. Use VANDAZOLE with caution in patients treated with lithium and consider monitoring lithium serum concentrations while on VANDAZOLE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b121e14-011c-4fca-917b-b7b188a797b2"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Cimetidine</h2>
<p class="First">Use of oral metronidazole with cimetidine may prolong the half-life and decrease plasma clearance of metronidazole. No dose adjustment of VANDAZOLE is necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_de5e86cb-fb35-43e7-ae3e-e4cafd102c2c"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_9de22e16-cb2f-4a89-8f5e-f786d1ba135c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_8f8f3c75-5101-4151-bb6a-beb651488559"></a><a name="section-8.1.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_id_352dc1c8-b573-4152-89e1-263031ff3c3a"></a><a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>VANDAZOLE should be used during pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women.</p>
<p>There are published data from case-control studies, cohort studies, and two meta-analyses that include more than 5000 pregnant women who used metronidazole systemically during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span>, with or without <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, in infants exposed to metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized, placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of systemic antibiotic treatment (including metronidazole) for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following systemic metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.</p>
<p>Oral reproductive toxicity studies have been performed in mice at doses up to six times the recommended human dose based on body surface area comparisons and have revealed no evidence of impaired fertility or harm to the fetus. However, in a single small study where the drug was administered intraperitoneally, some intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed. </p>
<p>Animal studies have shown that metronidazole crosses the placental barrier and enters the fetal circulation rapidly. Because animal reproduction studies are not always predictive of human response, and because metronidazole crosses the placental barrier and is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_3ad0e05c-f56a-424d-b617-3d5754cd4ddb"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when VANDAZOLE is administered to a nursing woman. Following oral metronidazole administration, concentrations of metronidazole in human milk are similar to concentrations in plasma. Since some metronidazole is systemically absorbed following vaginal administration of metronidazole, excretion in human milk is possible.</p>
<p>Because of the potential for tumorigenicity shown for metronidazole in animal studies, a decision should be made whether to discontinue nursing or to discontinue VANDAZOLE, taking into account the importance of the therapy to the mother. A nursing mother may choose to pump and discard her milk for the duration of VANDAZOLE therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a31cad50-44a4-4d69-9c4b-6f9b3e21d357"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of VANDAZOLEÂ  in the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> in post-menarchal females have been established on the extrapolation of clinical trial data from adult women. The safety and efficacy of VANDAZOLEÂ  in pre-menarchal females have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_83cc590e-879e-4db5-afb7-28efadcbbc11"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies with VANDAZOLEÂ  did not include sufficient numbers of subjects 65 years of age or older to determine whether they respond differently than younger subjects. Other reported clinical experience in using metronidazole gel, 1% has not identified differences in responses between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_9c1a78c5-8d8c-40ec-aba1-0fd1eda3e121"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no human experience with overdosage of metronidazole vaginal gel. Vaginally applied metronidazole gel, 0.75% could be absorbed in sufficient amounts to produce systemic effects [<span class="Italics">see</span><span class="Italics">Warnings and Precautions</span><span class="Italics">(<a href="#i4i_warnings_precautions_id_2a95692f-61c3-4d31-9cca-089dab5837c9">5</a>) and Adverse Reactions</span><span class="Italics">(<a href="#i4i_warnings_precautions_id_2a95692f-61c3-4d31-9cca-089dab5837c9">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0b5d961c-4b25-419e-a5c6-f75ae96f1014"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VANDAZOLEÂ  (metronidazole vaginal gel, 0.75%) is the vaginal dosage form of the nitroimidazole antimicrobial metronidazole at a concentration of 0.75%. Chemically, metronidazole is a 2-methyl-5-nitroimidazole-1-ethanol. </p>
<div class="Figure"><img alt="Structural formula for metronidazole" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-01.jpg"></div>
<p>C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span>      M.W. 171.16</p>
<p>VANDAZOLEÂ  is a colorless to yellow gel, containing metronidazole at a concentration of 7.5 mg/g (0.75%). The gel also contains edetate disodium, hypromellose, methylparaben, propylene glycol, propylparaben, purified water, and sodium hydroxide (to adjust pH).</p>
<p>Each applicator full of 5 grams of vaginal gel contains approximately 37.5 mg of metronidazole.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_96a797cb-0f4d-402f-9585-3deafe2dfbef"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_1d1067b6-3fd1-4013-ad5d-c5885e5cdb6a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Metronidazole is an antibacterial drug [<span class="Italics">see Clinical Pharmacology, Microbiology (<a href="#i4i_microbiology_id_a191e39d-9dd0-4d6d-9d20-b5c1b789b417">12.4</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3fc2a706-fed6-41e8-8c43-11935da62b71"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Healthy Subjects</span></p>
<p>Following a single, intravaginal 5 gram dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole) to 38 healthy female subjects, a mean maximum serum metronidazole concentration of 281 ng/mL was reported (range: 134 to 464 ng/mL). The average time to achieve this C<span class="Sub">max</span> was 9.5 hours (range: 4 to 17 hours) after dosing with metronidazole vaginal gel. This C<span class="Sub">max</span> is approximately 2% of the mean maximum serum concentration reported in healthy subjects administered a single, oral 500 mg dose of metronidazole (mean C<span class="Sub">max</span> = 12,785 ng/mL).</p>
<p>The extent of exposure [area under the curve (AUC)] of metronidazole, when administered as a single intravaginal 5 gram dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole), was 5,989 ngâ€¢hr/mL (range: 2,797 to 10,515 ngâ€¢hr/mL). This AUC<span class="Sub">0-</span><span class="Sub">âˆž</span> is approximately 5% of the reported AUC of metronidazole following a single oral 500 mg dose of metronidazole approximately 125,000 ngâ€¢hr/mL.</p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></span></p>
<p>Following single and multiple 5 gram doses of a similar metronidazole vaginal gel product to 4 patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, a mean maximum serum metronidazole concentration of 214 ng/mL on day one and 294 ng/mL (range: 228 to 349 ng/mL) on day five were reported. Steady state metronidazole serum concentrations following oral dosages of 400 to 500 mg BID have been reported to range from 6,000 to 20,000 ng/mL.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_a191e39d-9dd0-4d6d-9d20-b5c1b789b417"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>The intracellular targets of action of metronidazole on anaerobes are largely unknown. The 5-nitro group of metronidazole is reduced by metabolically active anaerobes, and studies have demonstrated that the reduced form of the drug interacts with bacterial DNA. However, it is not clear whether interaction with DNA alone is an important component in the bactericidal action of metronidazole on anaerobic organisms. </p>
<p><span class="Bold">Activity <span class="Italics">In Vitro</span></span></p>
<p>Metronidazole is an antibacterial agent active <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<p><span class="Italics">Bacteroides</span> spp.</p>
<p><span class="Italics">Gardnerella vaginalis</span></p>
<p><span class="Italics">Mobiluncus</span> spp.</p>
<p><span class="Italics">Peptostreptococcus</span> spp.</p>
<p>Standard methodology for the susceptibility testing of the potential <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> pathogens, <span class="Italics">Gardnerella vaginalis</span> and <span class="Italics">Mobiluncus</span> spp., has not been defined. Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> [<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_a492c4f7-73b1-40ab-a696-3842e32beb12">14</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_f250731c-8bf9-41ec-8e08-3aedc9dec966"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_7ec24807-6ab6-465a-b59a-b2250f20fec6"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Metronidazole has shown evidence of carcinogenic activity after chronic oral administration in mice and rats. Pulmonary tumors and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> were reported in several oral mouse studies in which mice were dosed at 75 mg/kg and above (about 5 times the clinical human dose based on body surface area comparison). <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">Malignant liver tumors</span> were reported in male mice dosed at doses equivalent to a human dose of 41 mg/kg/day (33 times the recommended clinical dose based on body surface area comparisons). Chronic oral dosing of metronidazole in rats at doses above 150 mg/kg (about 20 times the clinical human dose based on body surface area comparison) has resulted in mammary and hepatic tumors. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative. Although no life-time studies were performed to evaluate the carcinogenic potential of VANDAZOLEÂ  (metronidazole vaginal gel, 0.75%), published data have shown that intravaginal administration of metronidazole to Wistar rats for 5 days, at doses 26 times the recommended human dose based on body surface area comparisons, has resulted in an increased frequency of micronuclei in rat vaginal mucosal cells. </p>
<p>Metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro</span> assay systems. In addition, a dose dependent increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosome aberrations has been reported in one study of patients with Crohnâ€™s disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in a second study, no increase in chromosome aberrations was reported in patients with Crohnâ€™s disease who were treated with metronidazole for 8 months. </p>
<p>Fertility studies have been performed in mice up to six times the recommended human oral dose (based on mg/m<span class="Sup">2</span>) and have revealed no evidence of impaired fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_a492c4f7-73b1-40ab-a696-3842e32beb12"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">A single, randomized, double-blind, active-controlled clinical trial was conducted to evaluate the efficacy of VANDAZOLE for the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. A clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> was defined by the presence of a homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> include (a) markedly reduced or absent <span class="Italics">Lactobacillus</span> morphology, (b) predominance of <span class="Italics">Gardnerella</span> morphotype, and (c) absent or few white blood cells. Non-pregnant females at least 18 years of age were randomized to receive treatment with either VANDAZOLE or another formulation of metronidazole vaginal gel 0.75% once daily at bedtime for 5 days. The modified intent-to treat population (patients who received study medication and had a Nugent score â‰¥ 4) consisted of 229 VANDAZOLE patients and 243 patients treated with another vaginal formulation of metronidazole. Therapeutic Cure defined as a clinical cure and Nugent score &lt; 4 was assessed Day 22-31. Table 1 shows the therapeutic, clinical and Nugent score cure rates in this trial. The therapeutic cure rate was 42.8% for the VANDAZOLE group and 30.9% for the comparator group (95% confidence interval about the 11.9% difference in therapeutic cure rate: 2.8% to 21.0%).</p>
<a name="id_64f7ca33-6f36-40f4-8207-06acbf769c00"></a><table border="single" width="443">
<caption><span>Table 1 Efficacy of Vandazole for the Treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span> in a Randomized, Double-Blind Active Controlled Study<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="25.0%">
<col width="18.9%">
<col width="22.3%">
<col width="33.7%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Modified intent-to-treat population</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Outcome</td>
<td class="Botrule Rrule" align="center" valign="top">Vandazole<br>n = 229</td>
<td class="Botrule Rrule" align="center" valign="top">Active Control<br>n = 243</td>
<td class="Botrule Rrule" align="center" valign="top">Treatment Difference (%)<br>[95% Confidence Interval]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">% Cure</td>
<td class="Botrule Rrule" align="center" valign="top">% Cure</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Therapeutic Cure</td>
<td class="Botrule Rrule" align="center" valign="top">42.8</td>
<td class="Botrule Rrule" align="center" valign="top">30.9</td>
<td class="Botrule Rrule" align="center" valign="top">11.9 [2.8, 21.0]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Clinical Cure</td>
<td class="Botrule Rrule" align="center" valign="top">52.4</td>
<td class="Botrule Rrule" align="center" valign="top">45.3</td>
<td class="Botrule Rrule" align="center" valign="top">7.1 [-2.3, 16.5]</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Nugent Score Cure</td>
<td class="Rrule" align="center" valign="top">52.0</td>
<td class="Rrule" align="center" valign="top">41.1</td>
<td class="Botrule Rrule" align="center" valign="top">10.9 [1.5, 20.3]</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_abe75e2c-9b53-46d6-9e5b-8db7271596e8"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">VANDAZOLEÂ  (metronidazole vaginal gel, 0.75%) is supplied in a 70 gram tube and packaged with 5 vaginal applicators.</p>
<p>Store at 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [See USP Controlled Room Temperature]. Avoid exposure to extreme heat or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>. Protect from freezing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_f43b952d-2b6f-4ec4-8bbe-45a7c8010dd2"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0321e09c-31b9-49fd-9b55-25977b04cb6b"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Interaction with Alcohol</h2>
<p class="First">Instruct the patient not to consume alcoholic beverages and preparations containing ethanol or propylene glycol during and for at least 3 days after treatment with VANDAZOLE [<span class="Italics">see Contraindications (<a href="#i4i_section_id_97bf5f4b-bf64-40f4-9322-659929a88714">4.3</a>) and Drug Interactions (<a href="#i4i_section_id_1cc53620-cde0-4bdf-810e-9d189f1e5bf6">7.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f3570dd5-f260-49ca-8bae-04743200a517"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Drug Interactions</h2>
<p class="First">Instruct the patient not to use VANDAZOLE if disulfiram had been used within the last two weeks [<span class="Italics">see Contraindications (<a href="#i4i_section_id_98cb0c9d-7ce1-4131-bc21-984c1abe325e">4.2</a>)</span>], and to inform their healthcare provider if they are taking oral anticoagulants, or lithium [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_031c4a2d-a899-45a6-9faf-1c036484b0cf">7.3</a>, <a href="#i4i_section_id_c5c21511-18d9-4c63-a107-3f279d658b13">7.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1602ecc7-291e-4a11-8df4-087191ada116"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Vaginal Intercourse and Use with Vaginal Products</h2>
<p class="First">Instruct the patient not to engage in vaginal intercourse, or use other vaginal products (such as tampons or douches) during treatment with VANDAZOLE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33ce28b3-6647-46b6-b509-0294820223e5"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Fungal <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal Infections</span></h2>
<p class="First">Inform the patient that vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> can occur following use of VANDAZOLE and may require treatment with an antifungal drug [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_c9fc8ffc-4f44-4378-97e9-2250b09ca7a8">6.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0266f93b-6ff4-4b1c-9f63-cd645dc146dd"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Human Milk Feeding</h2>
<p class="First">Advise women that they may consider discontinuing milk feeding or pump and discard their milk during treatment and for 24 hours after the last dose of VANDAZOLE [<span class="Italics">see Use in Specific Populations (<a href="#i4i_nursing_mothers_id_3ad0e05c-f56a-424d-b617-3d5754cd4ddb">8.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_348f01c4-1651-4545-93b6-b35df077adb3"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Accidental Exposure to the Eye</h2>
<p class="First">Inform the patient that VANDAZOLE contains ingredients that may cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water and consult a healthcare provider.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23e43bb8-cb8d-4026-9fa6-bbabf949d9be"></a><a name="section-15.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">Vaginal Irritation</span></h2>
<p class="First">Inform the patient to discontinue use and consult a healthcare provider if <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">vaginal irritation</span> occurs with use of VANDAZOLE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_247a2d54-583e-4422-86ec-a4ff9c840646"></a><a name="section-15.8"></a><p></p>
<h2>17.8 Administration of Drug</h2>
<p class="First">Instruct the patient that VANDAZOLE (metronidazole vaginal gel, 0.75%) is supplied with 5 vaginal applicators. For once daily dosing, one applicator should be used per dose. See <span class="Bold">DIRECTIONS FOR USE</span> for complete instructions on how to use the product and the vaginal applicator.</p>
<p>US Patent No. 7,456,207</p>
<p>Manufactured For:</p>
<p><span class="Bold">UPSHER-SMITH LABORATORIES, INC.</span></p>
<p>Minneapolis, MN 55447</p>
<p>Rev. F 1/2011</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_679dd42d-82ac-4ffd-810d-35799d399b00"></a><a name="section-16"></a><p></p>
<h1>Patient instructions for use</h1>
<p class="First"><span class="Bold">VANDAZOLE<span class="Sup">Â®</span> (van-DA-zole)<br>(metronidazole vaginal gel, 0.75%)</span></p>
<p><span class="Bold">For vaginal use only.</span></p>
<p><span class="Bold">Do not put VANDAZOLE in your eyes, mouth, or on your skin.</span></p>
<p>Read this Patient Instructions for Use before you start using VANDAZOLE. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">Instructions for use:</span></p>
<div class="Figure">
<img alt="Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-02.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Figure">
<img alt="Cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-03.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Figure">
<img alt="Applicator" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-04.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Figure">
<img alt="Barrel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-05.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Figure">
<img alt="Plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-06.jpg"><p class="MultiMediaCaption"></p>
</div>
<p><span class="Bold">1. Filling the applicator</span></p>
<ul><li>Remove the cap and puncture the metal seal on the tube with the pointed tip of the cap. (See Figure A)</li></ul>
<div class="Figure">
<img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-07.jpg"><p class="MultiMediaCaption"></p>
</div>
<ul><li>Screw the end of applicator onto the tube. (See Figure B)</li></ul>
<div class="Figure">
<img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-08.jpg"><p class="MultiMediaCaption"></p>
</div>
<ul><li>Slowly squeeze the gel out of tube and into the applicator. The plunger will stop when the applicator is full. (See Figure C)</li></ul>
<div class="Figure">
<img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-09.jpg"><p class="MultiMediaCaption"></p>
</div>
<ul><li>Unscrew the applicator and replace the cap on the tube.</li></ul>
<p><span class="Bold">2. Inserting the applicator</span></p>
<ul>
<li>You can insert the applicator into your vagina:<ul>
<li>while you lie on your back with your knees bent or</li>
<li>in any position that is comfortable for you</li>
</ul>
</li>
<li>Hold the filled applicator by the barrel, and gently insert into your vagina as far as it will comfortably go. (See Figure D)</li>
</ul>
<div class="Figure">
<img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-10.jpg"><p class="MultiMediaCaption"></p>
</div>
<ul>
<li>Slowly push the plunger in until all of the gel goes into your vagina (See Figure D).</li>
<li>Take the empty applicator out of your vagina.</li>
</ul>
<p><span class="Bold">3. Care of the applicator</span></p>
<p><span class="Bold">This product comes with 5 vaginal applicators.</span></p>
<ul><li>After use, throw away the empty applicator in the trash.</li></ul>
<p><span class="Bold">While you use VANDAZOLE you should not have vaginal intercourse or use other vaginal products (such as tampons or douches).</span></p>
<p><span class="Bold">If <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">vaginal irritation</span> develops when you use VANDAZOLE, discontinue use and consult your healthcare provider.</span></p>
<p><span class="Bold">If you get VANDAZOLE in your eye, rinse your eye with cool tap water and consult a healthcare provider.</span></p>
<p><span class="Bold">How should I store VANDAZOLE?</span></p>
<ul>
<li>Store VANDAZOLE at 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Avoid exposure to extreme heat or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>. Avoid freezing VANDAZOLE.</li>
<li>Keep this and all medicines out of reach of children. </li>
</ul>
<p><span class="Bold">RX Only</span></p>
<p>Manufactured For:</p>
<p><span class="Bold">UPSHER-SMITH LABORATORIES, INC.</span></p>
<p>Minneapolis, MN 55447</p>
<p>Rev. C 12/2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_766c94ce-d39d-42ec-9669-314d5325e350"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, part 1 of 2</h1>
<div class="Figure"><img alt=" Vandazole (Metronidazole Vaginal Gel, 0.75%) 70 grams Tube, Carton Label, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_74433269-b3da-4a23-80e8-d02fa17b4128"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, part 2 of 2</h1>
<div class="Figure"><img alt=" Vandazole (Metronidazole Vaginal Gel, 0.75%) 70 grams Tube, Carton Label, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=27d71471-8f89-4a1e-8c55-020a58961454&amp;name=02c677d0-e310-4207-8958-9873f5819be6-12.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f73f1c8d-94f2-4554-bf8e-82291f4cdabf"></a><a name="section-18.1"></a><p></p>
<h2>Vandazole (Metronidazole Vaginal Gel, 0.75%) 70 grams Tube, Carton Text</h2>
<p class="First">NDC 0245-0860-70</p>
<p><span class="Bold">VANDAZOLE<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(Metronidazole Vaginal Gel, 0.75%)</span></p>
<p><span class="Bold">with 5 applicators</span></p>
<p>FOR INTRAVAGINAL USE ONLY.</p>
<p>(NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE.)</p>
<p><span class="Bold">Rx only</span></p>
<p>Net Wt. 70 grams</p>
<p><span class="Bold">UPSHER-SMITH</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANDAZOLEÂ 		
					</strong><br><span class="contentTableReg">metronidazole gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0245-0860</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">7.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (colorless to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0245-0860-70</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">70 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021806</td>
<td class="formItem">10/04/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Upsher-Smith Laboratories, Inc.
							(047251004)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Teva Pharmaceuticals USA Inc (118234421)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>02c677d0-e310-4207-8958-9873f5819be6</div>
<div>Set id: 27d71471-8f89-4a1e-8c55-020a58961454</div>
<div>Version: 4</div>
<div>Effective Time: 20131017</div>
</div>
</div>Â <div class="DistributorName">Upsher-Smith Laboratories, Inc.</div></p>
</body></html>
